浙江华海药业股份有限公司 关于“华海转债”预计触发转股价格向下修正的提示性公告

Group 1 - The company, Zhejiang Huahai Pharmaceutical Co., Ltd., has issued convertible bonds with a total amount of 1,842.60 million bonds, each with a face value of 100.00 yuan, totaling 184,260.00 million yuan [3] - The convertible bond, referred to as "Huahai Convertible Bond," is listed on the Shanghai Stock Exchange with the code "110076" and has a maturity period of six years from the issuance date [3] - The conversion price for the bonds is set at 33.06 yuan per share, with the conversion period running from May 6, 2021, to November 1, 2026 [2] Group 2 - The company anticipates that the conditions for a downward adjustment of the conversion price may be triggered, as the stock price has been below 80% of the current conversion price for 10 trading days within a 30-day period [6] - If the downward adjustment condition is triggered, the company will convene a board meeting to decide whether to adjust the conversion price and will disclose the decision in a timely manner [6][5] - The adjustment process requires a two-thirds majority approval from shareholders present at the meeting, excluding those holding the convertible bonds [4] Group 3 - The company has previously announced on April 26, 2025, that it would not adjust the conversion price of the "Huahai Convertible Bond" [6] - The company is obligated to disclose any decisions regarding the adjustment of the conversion price in accordance with the regulations set by the Shanghai Stock Exchange [6][5] - Investors can refer to the prospectus published on October 29, 2020, for more information regarding the "Huahai Convertible Bond" [7]